Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HUA MEDICINE

(Incorporated in the Cayman Islands with limited liability)

(stock code: 2552)

VOLUNTARY ANNOUNCEMENT UPDATE REGARDING RECENT BUSINESS DEVELOPMENTS

HUA MEDICINE ANNOUNCES POSITIVE RESULTS OF THE COMBINATION STUDY OF DORZAGLIATIN WITH EMPAGLIFLOZIN (A SGLT-2 INHIBITOR)

This announcement is made **Company**

Group

about the latest business updates of the Group.

Hua Medicine today announces the positive results of the clinical study HMM0112. HMM0112 is a Phase I trial conducted in the United States in Type 2 Diabetes (T2D) patients with insufficiently controlled blood glucose levels while on

-2 inhibitor) as either monotherapy or combination therapy. The PK results demonstrated no impact of dorzagliatin (75 mg BID) and empagliflozin (25 mg QD) on their respective PK properties under co-administration, supporting their combination use in the clinical setting, while the PD results demonstrated a clear synergistic effect in efficacy under combination

-2 inhibitors are a relatively newer class of oral medications for the treatment of T2D patients, in addition to the blood sugar control, they were found to have the effect to lower blood pressure and reduce body weight. Their global sales in 2019 were approximately 6 billion US

Hua is a leading, clinical-stage innovative drug development company in China focused on developing novel therapies for the treatment of diabetes. F*n4h(de)4d( )-119b y a eec

-ang.stmgeasfc Enye2(a)-9(0)(-94(bd))-2(79(4(ie)-7(D)-7(e)(in

entree(e)4urs ae-5(rnu)-6(a)4(pi)-3onael tment Hua aa c
cCde

a diabetein 3(two(30(Pm)-3h(a)4use)3 y)20I 30(tri(a3(lis 279(in 2(C)-2(hina 329(a)4ndf 30(v(a)4riousf 30((e)4(